Trial Profile
A Randomized, Cross-Over Study to Evaluate the Suppressive Effect of High-Dose Acyclovir Versus Once Daily Valacyclovir on Herpes Simplex Virus Type 2 Genital Shedding in Herpes Simplex Virus-2 Seropositive Adults.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 08 Sep 2023
Price :
$35
*
At a glance
- Drugs Valaciclovir (Primary) ; Aciclovir
- Indications Herpes genitalis; Herpes simplex virus type 2 infections
- Focus Therapeutic Use
- 05 Jan 2012 Results published ahead of print in the lancet.
- 05 Jan 2012 Status changed from active, no longer recruiting to completed, results have been published.
- 18 May 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.